Physician profile
Jason Michael Feuerman
NPI 1205147634
$4,095.36
in general payments reported to CMS, 2019-2025
24 companies · $878 in 2025
The $878 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,270 · 2020: $138 · 2021: $17.63 · 2022: $711 · 2023: $630 · 2024: $451 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,959.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,264.22 | 2019-2024 | Tecnis Simplicity, Tecnis Iol |
| Abbvie INC. | $683.98 | 2022-2025 | |
| Rxsight INC | $348.01 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Alcon Vision LLC | $295.06 | 2022-2025 | Clareon, Tryptyr, Rocklatan |
| Biotissue Holdings INC. | $229.56 | 2019-2023 | |
| Harrow Eye, LLC | $144.34 | 2025 | Vevye |
| Genentech USA, INC. | $141.42 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $135.01 | 2022 | |
| Mallinckrodt Enterprises LLC | $125.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $114.86 | 2019-2023 | |
| Amgen INC. | $105.57 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $103.56 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Oyster Point Pharma, INC. | $65.68 | 2022-2025 | Ryzumvi, Tyrvaya |
| Dompe US, INC. | $55.60 | 2022-2025 | Oxervate |
| Ocular Therapeutix, INC. | $51.86 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $42.20 | 2025 | |
| Carl Zeiss Meditec, INC. | $36.11 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $35.82 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.05 | 2019 | |
| Mallinckrodt Hospital Products INC. | $24.69 | 2020 | |
| Rayner Intraocular Lenses Limited | $21.77 | 2023 | Omidria, Rayone Aspheric, Rayone Emv |
| Tearlab Corp | $15.35 | 2022 | |
| Thea Pharma INC. | $14.92 | 2024 | Iyuzeh |
| Shire North American Group INC | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Feuerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.